Avadel Pharmaceuticals plc

NasdaqGM AVDL

Avadel Pharmaceuticals plc Operating Income for the year ending December 31, 2023: USD -137.85 M

Avadel Pharmaceuticals plc Operating Income is USD -137.85 M for the year ending December 31, 2023, a -39.86% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Avadel Pharmaceuticals plc Operating Income for the year ending December 31, 2022 was USD -98.56 M, a -15.21% change year over year.
Avadel Pharmaceuticals plc Operating Income for the year ending December 31, 2021 was USD -85.55 M, a -133.34% change year over year.
Avadel Pharmaceuticals plc Operating Income for the year ending December 31, 2020 was USD -36.66 M, a -117.88% change year over year.
Avadel Pharmaceuticals plc Operating Income for the year ending December 31, 2019 was USD -16.83 M, a 83.96% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGM: AVDL

Avadel Pharmaceuticals plc

CEO	Mr. Gregory J. Divis Jr.
IPO Date	June 7, 1996
Location	Ireland
Headquarters	10 Earlsfort Terrace
Employees	154
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years